A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY OF PF-05280586VERSUS RITUXIMAB FOR THE FIRST-LINE TREATMENT OF PATIENTSWITH CD20-POSITIVE, LOW TUMOR BURDEN, FOLLICULAR LYMPHOMA
Not Applicable
- Conditions
- -C827 Other types of follicular lymphomaOther types of follicular lymphomaC827
- Registration Number
- PER-073-14
- Lead Sponsor
- PFIZER S.A.,
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 5
Inclusion Criteria
1.Male or female patients aged 18 years or older.
2.Histologically confirmed, Grade 1-3a, untreated, CD20-positive follicular lymphoma (containing no elements of diffuse large B-cell lymphoma).
NOTE: Patients can be entered based on a diagnosis of CD20+ follicular lymphoma confirmed at the investigational site. Archival tissue must be sent to the central pathology reviewer for confirmation of diagnosis. Patients must have tissue available for the central pathology review to be enrolled.
(see dossier to see information complete)
Exclusion Criteria
1. Patients who are not candidates for rituximab monoterapy
(see dossier for complete information)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method